Back to Messages Index Page



DEAN BONLIE, D.D.S., graduated with honors from Loma Linda University in 1962.

Since that date, his occupational journey has been varied and colorful. However, in the last 14 years he has found his real fulfillment in the study of magnetism as it relates to health, and devoted his entire energy and focus in that arena. His scientific theory on the action of magnetism on living tissue has made him a widely accepted authority in this field. He is now recognized as an expert researcher, inventor, consultant and lecturer on biomagnetism. The basis of his theory is that our only natural source of magnetism is environmental—from the earth—but now that this source is so drastically depleted, it appears to have a distinct impact on life and health. Initially, his research led to the design and production of the ONLY magnetic sleep pad which correctly restores an earth-type magnetic field back to the body. It is patented and marketed by his company, Magnetico Inc.

The positive results obtained from the low gauss sleep pads stimulated his research into higher strength magnetic fields and the subsequent development of the “Magnetic Molecular Energizer” (MME) device. This is a large clinical magnetic high-strength treatment device (also patented), weighing 10,000 lbs., being operated in six Advanced Magnetic Research Institutes* (AMRI's) in the USA and Canada.

Dr. Bonlie is currently the President of the North American Academy of Magnetic Therapy (NAAMT0. He has taught courses in magnetic treatment for the Integrative Medicine post-doctoral degree offered by Capital University in Washington, D.C. He also presents accredited courses at numerous complementary and alternative conferences offering continuing education for doctors and other medical personnel.

* Advanced Magnetic Research Institute (AMRI) centers are located at the following sites:

AMRI of NW Ohio provides MME treatment under the guidelines of an Investigational Review Board, consistent with FDA regulations.

 Please note that MME treatment is considered to be experimental by the FDA. Although many patients have improved, no guarantee of success is implied.